Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

Similar articles for PubMed (Select 23052131)

1.

Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Wang DM, Liu L, Fan L, Zou ZJ, Zhang LN, Yang S, Li JY, Xu W.

Cancer Biol Ther. 2012 Dec;13(14):1522-8. doi: 10.4161/cbt.22252. Epub 2012 Oct 10.

2.

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.

Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G.

Clin Cancer Res. 2010 Mar 15;16(6):1824-33. doi: 10.1158/1078-0432.CCR-09-3031. Epub 2010 Mar 9.

3.

S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.

Liu L, Fan L, Fang C, Zou ZJ, Yang S, Zhang LN, Li JY, Xu W.

Cancer Sci. 2012 Dec;103(12):2056-63. doi: 10.1111/cas.12008. Epub 2012 Oct 10.

PMID:
22937789
4.

The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.

Zhu HJ, Liu L, Fan L, Zhang LN, Fang C, Zou ZJ, Li JY, Xu W.

Leuk Lymphoma. 2013 Dec;54(12):2712-9. doi: 10.3109/10428194.2013.787613. Epub 2013 Apr 30.

PMID:
23517560
5.

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.

Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.

6.

Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.

Xu M, Fan L, Miao KR, Liu P, Xu W, Li JY.

Med Oncol. 2012 Sep;29(3):2102-10. doi: 10.1007/s12032-011-0054-2. Epub 2011 Sep 1.

PMID:
21881978
7.

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, Cavazzini F, Campioni D, Fanin R, Cuneo A, Zauli G.

Blood. 2006 May 15;107(10):4122-9. Epub 2006 Jan 26.

9.

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.

Blood. 2003 Jun 15;101(12):4944-51. Epub 2003 Feb 20.

10.

P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.

Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MR, Begleiter A.

Leuk Lymphoma. 1997 Aug;26(5-6):435-49.

PMID:
9389352
11.

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.

Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, Fegan C, Pepper C.

Leuk Res. 2011 Jun;35(6):750-6. doi: 10.1016/j.leukres.2010.10.022. Epub 2010 Nov 18.

PMID:
21093051
12.

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.

Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P.

Clin Cancer Res. 2011 Feb 15;17(4):762-70. doi: 10.1158/1078-0432.CCR-10-2572. Epub 2010 Nov 24.

13.

Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.

Zauli G, di Iasio MG, Secchiero P, Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V.

Curr Cancer Drug Targets. 2009 Jun;9(4):510-8.

PMID:
19519319
14.

[Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].

Xu W, Shen QD, Yu H, Qiao C, Wu YJ, Liu Q, Zhu DX, Miao KR, Li JY.

Zhonghua Xue Ye Xue Za Zhi. 2009 Jan;30(1):8-12. Chinese.

PMID:
19563027
15.

CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.

Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, Petersen JH, Leffers H.

Eur J Haematol. 2006 Jun;76(6):455-64. Epub 2006 Mar 9.

PMID:
16529606
16.

Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.

Wang YH, Zou ZJ, Liu L, Zhang LN, Fang C, Zhu DX, Fan L, Li JY, Xu W.

J Cancer Res Clin Oncol. 2012 Jun;138(6):1011-7. doi: 10.1007/s00432-012-1177-3. Epub 2012 Feb 24.

PMID:
22362302
17.

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC.

J Clin Oncol. 2007 Mar 1;25(7):799-804. Epub 2007 Feb 5.

18.

Significance of VH genes mutation status for prognosis of CLL patients.

Bilous N, Abramenko I, Kryachok I, Bazyka D, Chumak A, Bebeshko V.

Exp Oncol. 2005 Dec;27(4):325-9.

PMID:
16404355
19.

The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.

Chen L, Li J, Zheng W, Zhang Y, Wu Y, Li L, Qian S, Xu W.

Leuk Lymphoma. 2007 Sep;48(9):1785-92.

PMID:
17786715
20.

[Detection of puma mRNA levels by real-time quantitative RT-PCR in chronic lymphocytic leukemia and its clinical significance].

Zhu HJ, Xu W, Cao X, Fang C, Zhu DX, Dong HJ, Wang DM, Qiao C, Miao KR, Liu P, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):843-8. Chinese.

PMID:
20723285
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk